Up next

Autoplay

Durable responses to avelumab in patients with Merkel cell carcinoma

2 Views • 07/17/23
Share
Embed
administrator
administrator
Subscribers
0

Dr Kaufman speaks with ecancer at AACR 2017 about the effectiveness of anti-PD-L1 avelumab in treating Merkel cell carcinoma (MCC) in patients who had been previously treated with chemotherapy.

He describes results from 88 patients with metastatic disease, who at 6 months follow-up had 31% response, and 33% response at 1 year.

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay